Core Viewpoint - The share transfer plan of Huace Testing involves the transfer of up to 17.26 million shares to the actual controller's action group, which will not change the total shareholding of the actual controller and its concerted actors, maintaining a 22.06% stake in the company [1][2]. Group 1: Share Transfer Details - The transfer will occur through block trading and will not exceed 1.031% of the company's total share capital after excluding repurchased shares [1]. - The transfer period is set from July 21, 2025, to October 20, 2025, with trading prices determined by the secondary market [1]. - After the transfer, the actual controller's total shareholding will remain unchanged at 371,183,884 shares [1][2]. Group 2: Financial Performance - Huace Testing's revenue for 2022, 2023, and 2024 is reported as 5.13 billion, 5.60 billion, and 6.08 billion yuan respectively, showing an increase of 8.55% from 2023 to 2024 [2][3]. - The net profit attributable to shareholders for the same years is 9.03 billion, 9.10 billion, and 9.21 billion yuan, indicating a slight increase of 1.19% from 2023 to 2024 [2][3]. - The cash flow from operating activities for 2022, 2023, and 2024 is reported as 11.00 billion, 11.22 billion, and 10.63 billion yuan, with a decrease in 2024 [2][3]. Group 3: Recent Quarterly Performance - In Q1 2025, the company reported a revenue of 1.29 billion yuan, a year-on-year increase of 7.96% [4][5]. - The net profit attributable to shareholders for Q1 2025 is 136.19 million yuan, reflecting a 2.75% increase compared to the same period last year [4][5]. - The net cash flow from operating activities for Q1 2025 is reported at -89.94 million yuan, showing a significant improvement of 47.10% year-on-year [4][5].

博创 30 号资管计划、玄元 166 号私募基金拟通过大宗交易方式累计不超过 1,726 万股给实际控制人持有 100%份额的博时资管计划或玄元私募基金，即不超过公 司总股本（剔除回购股份后）的 1.031%。本次交易期间为公告披露之日起 15 个 交易日后的 3 个月内（2025 年 7 月 21 日至 2025 年 10 月 20 日），期间如遇法 律法规规定的窗口期则不得交易，交易价格根据二级市场情况确定。本次转让计 划完成后，博创 21 号资管计划、博创 29 号资管计划、博创 30 号资管计划、玄 元 166 号私募基金不再持有公司股票，实际控制人持有 100%份额的其他资管计 划或私募基金产品相应增加公司持股数量，交易前后实际控制人及一致行动人累 计持有公司的总股数不会变化，合计持有公司股票仍为 371,183,884 股，占公司 总股本 22.06%。 一、背景概述 证券代码：300012 证券简称：华测检测 公告编号：2025-033 华测检测认证集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 致行动人转让，不 ...

证券代码：300012 证券简称：华测检测 公告编号：2025-033 华测检测认证集团股份有限公司 关于实际控制人之一致行动人股份变动的预披露公告 计持有公司的总股数不会变化，合计持有公司股票仍为 371,183,884 股，占公司 总股本 22.06%。 一、背景概述 华测检测认证集团股份有限公司（以下简称"公司"）于 2021 年 1 月 5 日披露了《关于股东增加一致行动人及持股在一致行动人之间内部转让计划的提 示性公告》（公告编号：2021-001），本次一致行动人之间内部转让计划已于 2021 年 3 月 5 日实施完成，累计向资产管理计划/私募基金产品转让 23,472,510 股。 公司于 2021 年 8 月 24 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于股东 增加一致行动人及持股在一致行动人之间内部转让计划的提示性公告》，本次一 致行动人之间内部转让计划已于 2021 年 11 月 25 日实施完成，累计向资产管理 计划/私募基金产品转让 20,800,000 股。具体内容详见公司于 2021 年 03 月 05 日和 2021 年 11 月 27 日在巨潮资讯网披 ...

Core Viewpoint - The ultrasonic non-destructive testing (NDT) industry in China has developed rapidly, covering various industrial sectors, with a projected market size of 5.772 billion yuan in 2024, reflecting a year-on-year growth of 6.81% [1][17]. Overview - Non-destructive testing refers to methods that assess the properties and integrity of materials without causing damage, utilizing physical or chemical techniques to detect internal and surface defects [1]. - The main non-destructive testing methods include ultrasonic testing (UT), radiographic testing (RT), magnetic particle testing (MT), penetrant testing (PT), and eddy current testing (ET) [3]. Market Policy - Recent policies in China emphasize product quality and safety, mandating non-destructive testing across various industries to ensure compliance with standards [8][10]. - A series of regulations and action plans have been introduced to promote high-quality development in manufacturing and enhance the capabilities of inspection and testing services [8][10]. Industry Chain - The ultrasonic NDT industry comprises equipment manufacturers and service providers, with upstream suppliers including raw materials and components, and downstream markets spanning various sectors such as special equipment, rail transportation, and aerospace [11][13]. Market Demand - The special equipment sector represents the largest demand for non-destructive testing, accounting for approximately 30% of the market, followed by rail transportation at around 25% [13]. - The growth in infrastructure and manufacturing automation in the Asia-Pacific region, particularly in China, India, Japan, and South Korea, is driving market expansion [15]. Competitive Landscape - The ultrasonic NDT equipment market has high entry barriers, resulting in fewer participants and relatively mild competition, with key players including Shantou Ultrasonic Instrument Research Institute and Guangzhou Duopule Electronic Technology [19][22]. - The service market is more fragmented, with numerous small players, while larger institutions like China National Inspection Testing Group and Huace Testing hold significant market recognition [19][23]. Development Trends - The industry is expected to see increased demand from advanced manufacturing sectors such as electric vehicles and electronics, with ultrasonic testing technology expanding into non-metal and composite materials [26]. - There is a trend towards domestic substitution of high-end ultrasonic NDT equipment, driven by advancements in local research and development and government policies promoting self-sufficiency [26].

Group 1 - The core index, the China Securities Social Development Security Industry Theme Index, rose by 1.21% to 1596.77 points, with a trading volume of 34.7 billion yuan [1] - Over the past month, the index has decreased by 1.85%, down 11.26% over the last three months, and down 3.54% year-to-date [1] - The index includes no more than 100 securities from companies benefiting from social development security, covering sectors such as information security, environmental security, security equipment, and safety testing [1] Group 2 - The top ten holdings of the index are: Huace Testing (9.48%), Hikvision (8.05%), Zhongke Shuguang (3.6%), Wanfu Biology (2.93%), Meiya Optoelectronics (2.91%), Greeenmei (2.87%), Nanwang Technology (2.6%), Dahua Technology (2.43%), Aerospace Zhizhuang (2.35%), and Siwei Liekong (2.34%) [1] - The market share of the index's holdings is 67.16% from the Shenzhen Stock Exchange and 32.84% from the Shanghai Stock Exchange [1] Group 3 - The industry composition of the index's sample includes: 42.47% in industrials, 41.80% in information technology, 5.47% in utilities, 4.93% in communication services, 4.89% in healthcare, and 0.45% in finance [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December [2] Group 4 - Public funds tracking the index include Donghai China Securities Social Development Security [3]

证券代码：300012 证券简称：华测检测 公告编号：2025-031 华测检测认证集团股份有限公司 关于首期员工持股计划延期的公告 见书。 2019 年 9 月 11 日"兴全睿众华测检测特定客户资产管理计划"通过深圳证 券交易所大宗交易方式出售持有公司股份550万股，成交价格为12.19元/股。2020 年9月1日通过深圳证券交易所大宗交易系统出售员工持股计划持有的公司股份 110 万股，成交价格为 26.95 元/股。 2021 年 6 月 18 日，公司首期员工持股计划持有人会议审议通过首期员工持 股计划延期事项。同日，公司第五届董事会十六次会议审议通过《关于公司首期 员工持股计划延期的议案》，同意对公司首期员工持股计划存续期延长 24 个月， 即延长至 2023 年 8 月 18 日。关联董事对该议案进行回避表决，独立董事对延期 事项出具独立意见。 2023 年 7 月 4 日，公司首期员工持股计划持有人会议审议通过首期员工持 股计划延期事项。同日，公司第六届董事会六次会议审议通过《关于公司首期员 工持股计划延期及变更的议案》，同意对公司首期员工持股计划存续期延长 24 个月，即延长至 2025 年 ...

证券代码：300012 证券简称：华测检测 公告编号：2025-032 华测检测认证集团股份有限公司 关于终止第四期员工持股计划的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告！ 华测检测认证集团股份有限公司 华测检测认证集团股份有限公司（以下简称"公司"）于 2025 年 3 月 31 日召开第六届董事会第二十二次会议和第六届监事会第十五次会议，审议通过了 《关于<公司第四期员工持股计划（草案）>及其摘要的议案》《关于<公司第四 期员工持股计划管理办法>的议案》《关于提请股东大会授权董事会办理第四期 员工持股计划相关事宜的议案》等与第四期员工持股计划相关的议案。截至目前， 上述议案尚未提交公司股东大会审议，第四期员工持股计划尚未成立。 2025 年 6 月 23 日，公司召开第六届董事会第二十四次会议和第六届监事会 第十七次会议，审议通过了《关于终止第四期员工持股计划的议案》。 二、第四期员工持股计划终止的原因 公司董事会审议通过员工持股计划相关议案后，积极推进员工持股计划的相 关事宜。受关税政策及资本市场的变化，A 股市场整体波动加剧，股价 ...

证券代码：300012 证券简称：华测检测 公告编号：2025-030 华测检测认证集团股份有限公司 第六届监事会第十七次会议决议公告 华测检测认证集团股份有限公司第六届监事会第十七次会议于2025年6月20日 发出通知，2025年6月23日召开。本次会议采用现场结合通讯方式召开，会议应参 加监事3人，实际参加监事3人，分别为：陈炜明、张渝民、杜学志。本次会议召 开符合《公司法》和《公司章程》的有关规定。会议由公司监事会主席陈炜明先 生主持，经与会监事认真审议，形成如下决议： 一、会议以 3 票同意、0 票反对、0 票弃权，审议通过了《关于终止第四期员工持 股计划的议案》 监事会认为，公司终止实施第四期员工持股计划，不会对公司的发展战略、 经营规划等方面造成影响，也不会对公司的财务状况和经营成果产生影响。公司 将根据实际经营情况、市场环境的变化及员工意愿，选择合适的时机及方式，建 立长期有效的激励机制，充分调动公司核心管理人员和核心员工的积极性，使员 工利益与公司长远发展更紧密地结合，实现公司可持续发展。同时，公司不排除 在未来 12 个月内推出新的员工持股计划的可能。 体内容详见公司同日披露于巨潮资讯网（w ...

证券代码：300012 证券简称：华测检测 公告编号：2025-029 华测检测认证集团股份有限公司 第六届董事会第二十四次会议决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 华测检测认证集团股份有限公司（以下简称"公司"）第六届董事会第二十 四次会议于 2025 年 6 月 20 日发出会议通知，2025 年 6 月 23 日以现场结合通讯方 式召开。本次会议应参与董事 7 名，实际参与董事 7 名，分别为：万峰、申屠献 忠、钱峰、戚观成、曾繁礼、程海晋、刘志权。会议由董事长万峰主持，董事会 会议的举行和召开符合国家有关法律、法规及《公司章程》的规定。经充分讨论 和审议，会议形成决议如下： 一、会议以 7 票同意、0 票反对、0 票弃权，审议通过了《关于首期员工持股计划 延期的议案》 基于目前证券市场的情况，综合考虑公司实际发展状况，切实发挥员工持股 计划的激励作用，公司拟将首期员工持股计划存续期延长至 2027 年 12 月 31 日。 本次员工持股计划可以在延长期内出售股票，在存续期内，若员工持股计划所持 有的公司股票全部出售，员工持股计划可提前 ...

Group 1 - The CRO concept sector experienced a decline of 1.65%, ranking among the top declines in the concept sector, with notable declines from companies such as Saint Noble Bio, Meinohua, and Ruizhi Medicine [1][2] - Among the CRO concept stocks, 10 stocks saw price increases, with Wanbang Pharmaceutical, Puni Testing, and Huace Testing leading the gains at 6.96%, 3.37%, and 2.25% respectively [1][2] - The CRO concept sector faced a net outflow of 1.109 billion yuan in main funds, with 48 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2][3] Group 2 - The top net outflow stock was WuXi AppTec, with a net outflow of 337 million yuan, followed by Lianhua Technology, Ruizhi Medicine, and Kailai Ying with net outflows of 136 million yuan, 105 million yuan, and 86 million yuan respectively [2][3] - The stocks with the highest net inflow included Huace Testing, Dongcheng Pharmaceutical, and Jinshi Yao, with net inflows of 29.24 million yuan, 23.51 million yuan, and 15.25 million yuan respectively [2][4] - The overall market sentiment reflected a mixed performance across various concept sectors, with brain-computer interface leading the gains at 6.63% while the CRO concept lagged behind [2][4]